Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody
- Conditions
- Multiple sclerosis
- Registration Number
- EUCTR2005-001008-37-SE
- Lead Sponsor
- Sahlgrenska University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Multiple sclerosis patients aged 18-65 years treated by Rebif 22 microgram/dose for more than 1 year.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Insufficient patient compliance.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method